Evidence map›Paper›PMID 28664938›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2017

LEF1 is preferentially expressed in the tubal-peritoneal junctions and is a reliable marker of tubal intraepithelial lesions.

Elisa Schmoeckel, Ashley A Odai-Afotey, Michael Schleißheimer, Miriam Rottmann, Andrea Flesken-Nikitin, Lora H Ellenson, Thomas Kirchner, Doris Mayr, Alexander Yu Nikitin

Open access · bronzeAbstract read
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
4.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Stem Cell Pathology.Annual review of pathology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Elisa SchmoeckelInstitute of Pathology, Ludwig Maximilians University, Munich, Germany.
Ashley A Odai-AfoteyDepartment of Biomedical Sciences and Cornell Stem Cell Program, Cornell University, Ithaca, NY, USA.
Michael SchleißheimerInstitute of Pathology, Ludwig Maximilians University, Munich, Germany.
Miriam RottmannInstitute of Medical Information Processing, Biometry und Epidemiology, Ludwig Maximilians University, Munich, Germany.
Andrea Flesken-NikitinDepartment of Biomedical Sciences and Cornell Stem Cell Program, Cornell University, Ithaca, NY, USA.ORCID 0000-0003-3017-1399
Lora H EllensonDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
Thomas KirchnerInstitute of Pathology, Ludwig Maximilians University, Munich, Germany.
Doris MayrInstitute of Pathology, Ludwig Maximilians University, Munich, Germany.
Alexander Yu NikitinDepartment of Biomedical Sciences and Cornell Stem Cell Program, Cornell University, Ithaca, NY, USA.ORCID 0000-0002-3729-7982
Cornell University · USLudwig-Maximilians-Universität München · DEZimmer Biomet (Germany) · DE

Funding

Reproductive Sciences and Genomics Training ProgramT32HD052471 · NICHD · CORNELL UNIVERSITY · PI ROBERSON, MARK S · 2007 to 2016
$2.0M
Origins of Ovarian CarcinomaR01CA182413 · NCI · CORNELL UNIVERSITY · PI NIKITIN, ALEXANDER Y. · 2015 to 2019
$1.8M
NCI NIH HHS R01 CA182413NICHD NIH HHS T32 HD052471
6 · The paper itself

Abstract

Recently it has been reported that serous tubal intraepithelial carcinoma (STIC), the likely precursor of ovarian/extra-uterine high-grade serous carcinoma, are frequently located in the vicinity of tubal-peritoneal junctions, consistent with the cancer-prone features of many epithelial transitional regions. To test if p53 (aka TP53)-signatures and secretory cell outgrowths (SCOUTs) also localize to tubal-peritoneal junctions, we examined these lesions in the fallopian tubes of patients undergoing salpingo-oophorectomy for sporadic high-grade serous carcinomas or as a prophylactic procedure for carriers of familial BRCA1 or 2 mutations. STICs were located closest to the tubal-peritoneal junctions with an average distance of 1.31 mm, while SCOUTs were not detected in the fimbriated end of the fallopian tube. As many epithelial transitional regions contain stem cells, we also determined the expression of stem cell markers in the normal fallopian tube, tubal intraepithelial lesions and high-grade serous carcinomas. Of those, LEF1 was consistently expressed in the tubal-peritoneal junctions and all lesions, independent of p53 status. All SCOUTs demonstrated strong nuclear expression of β-catenin consistent with the LEF1 participation in the canonical WNT pathway. However, β-catenin was preferentially located in the cytoplasm of cells comprising STICs and p53 signatures, suggesting WNT-independent function of LEF1 in those lesions. Both frequency of LEF1 expression and β-catenin nuclear expression correlated with the worst 5-year patient survival, supporting important role of both proteins in high-grade serous carcinoma. Taken together, our findings suggest the existence of stem cell niche within the tubal-peritoneal junctions. Furthermore, they support the notion that the pathogenesis of SCOUTs is distinct from that of STICs and p53 signatures. The location and discrete patterns of LEF1 and β-catenin expression may serve as highly sensitive and reliable ancillary markers for the detection and differential diagnosis of tubal intraepithelial lesions.

Indexed as

AdultAgedAged, 80 and overbeta CateninBiomarkers, TumorBRCA1 ProteinBRCA2 ProteinCarcinoma in SituCase-Control StudiesFallopian Tube NeoplasmsFemaleHumansImmunohistochemistryKaplan-Meier EstimateLymphoid Enhancer-Binding Factor 1Middle Agedbeta CateninBiomarkers, TumorBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanCTNNB1 protein, humanLEF1 protein, humanLymphoid Enhancer-Binding Factor 1TP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID28664938
PMCPMC5604248
OpenAlexW2730805871

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.